conjugated estrogen


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.

con·ju·gat·ed es·tro·gen

an amorphous preparation of naturally occurring, water-soluble, conjugated forms of mixed estrogens obtained from the urine of pregnant mares (conjugated equine estrogen); the principal estrogen present is sodium estrone sulfate; suitable for parenteral, oral, and topical administration.

conjugated estrogen

[kon′jəgā′tid]
a mixture of sodium salts of estrogen sulfates, chiefly those of estrone, equilin, and 17-alpha-dihydroequilin. Conjugated estrogens may be prescribed to relieve postmenopausal vasomotor symptoms, such as hot flashes; to treat atrophic vaginitis, female hypogonadism, or primary ovarian failure; and to provide palliation in advanced prostatic carcinoma and metastatic breast cancer in selected patients. The drug is also used to treat and prevent osteoporosis. Continued use of estrogens can increase the risk of endometrial carcinoma, gallbladder disease, and thromboembolic disorders. Because of the danger of damage to the fetus, all female sex hormones are contraindicated during pregnancy. Among the adverse effects of conjugated estrogens are breakthrough bleeding, breast tenderness, nausea, headache, water retention, and skin eruptions. Current preliminary evidence suggests that there are no cardiovascular benefits to estrogen use during menopause, evidence that led to early discontinuation of the clinical study and changes in the product labeling. Coronary heart disease, the focus of the study, was actually increased in the treatment group, along with breast cancer, stroke, and thromboembolism. Topical agents rather than systemic estrogen should be used for treating vulvar or vaginal atrophy. Nonestrogen agents are recommended for the treatment and prevention of osteoporosis.

conjugated estrogen

An estrogenic drug, principally estrone and equilin, used to treat menopausal symptoms and to prevent osteoporosis.
See also: estrogen
References in periodicals archive ?
Bio-E-Gel offers an advantage over oral estrogen products by providing bio-identical estrogen that is not subject to first-pass liver metabolism, thereby avoiding known side effects associated with oral administration of conjugated estrogen.
625 mg of conjugated estrogens or to placebo in the first, fourth, and fifth SMART (Selective Estrogens, Menopause, and Response to Therapy) trials.
In the USA the predominant compounds are conjugated estrogens and medroxyprogesterone-acetate, whereas oestradiol combined with testosterone-like progestins is commonly used in Europe.
Our transdermal estradiol gel offers an important additional advantage over oral estrogen products by providing bio identical estrogen that is not subject to first-pass liver metabolism, thus avoiding further potential side effects associated with oral administration of conjugated estrogens.
On the first anniversary of a study by the National Institutes of Health (NIH) showing that estrogens increase the risk of breast cancer, heart attacks, and blood clots in women and with the news showing that hormone replacement therapy (HRT) contributes to dementia, Last Chance for Animals (LCA) found that pregnant mares are being sequestered and their foals slaughtered solely to collect the horses' urine to manufacture conjugated estrogens (Premarin[R]).
Although reef-building corals can take up significant amounts of unconjugated estrone from the water, it is not known whether corals or other organisms similarly can take up conjugated estrogens.
Conjugated estrogens, up to 25 mg IV given every 4 hours, and oral progesterone.
There exists a clinical preparation of conjugated estrogens that does come from pregnant mares' urine, Premarin.
the use of conjugated estrogens and bazedoxifene (Duavee) to manage hot flashes and menopausal bone loss
DUAVEE is also the first and only therapy to pair conjugated estrogens (CE) with an oestrogen agonist/antagonist also known as a selective oestrogen receptor modulator (SERM).
The combination of the selective estrogen receptor modulator (SERM) baze-doxifene and conjugated estrogens produced "very favorable" changes in lipid profiles and no clinically meaningful effects on coagulation parameters, fibrinolytic activity, or carbohydrate metabolism in the phase III SMART-1 trial, Dr.